(Q53359385)

English

Stage migration and increasing proportion of favorable-prognosis metastatic renal cell carcinoma patients: implications for clinical trial design and interpretation.

scientific article published in January 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

13 May 2018

http://europepmc.org/abstract/MED/19921736

Stage migration and increasing proportion of favorable-prognosis metastatic renal cell carcinoma patients: implications for clinical trial design and interpretation. (English)

1 reference

Europe PubMed Central

13 May 2018

http://europepmc.org/abstract/MED/19921736

renal cell carcinoma

1 reference

based on heuristic

inferred from title

metastatic renal cell carcinoma

1 reference

based on heuristic

inferred from title

4

1 reference

Europe PubMed Central

13 May 2018

http://europepmc.org/abstract/MED/19921736

author name string

Sujata Patil

1

1 reference

Europe PubMed Central

13 May 2018

http://europepmc.org/abstract/MED/19921736

Nicole Ishill

2

1 reference

Europe PubMed Central

13 May 2018

http://europepmc.org/abstract/MED/19921736

John Deluca

3

1 reference

Europe PubMed Central

13 May 2018

http://europepmc.org/abstract/MED/19921736

language of work or name

0 references

publication date

1 January 2010

1 reference

Europe PubMed Central

13 May 2018

http://europepmc.org/abstract/MED/19921736

1 reference

Europe PubMed Central

13 May 2018

http://europepmc.org/abstract/MED/19921736

116

1 reference

Europe PubMed Central

13 May 2018

http://europepmc.org/abstract/MED/19921736

2

1 reference

Europe PubMed Central

13 May 2018

http://europepmc.org/abstract/MED/19921736

347-354

1 reference

Europe PubMed Central

13 May 2018

http://europepmc.org/abstract/MED/19921736

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24713

7 January 2021

based on heuristic

inferred from DOI database lookup

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24713

7 January 2021

based on heuristic

inferred from DOI database lookup

Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24713

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24713

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic factors for survival of patients with stage IV renal cell carcinoma: memorial sloan-kettering cancer center experience.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24713

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic factors in patients with advanced renal cell carcinoma: development of an international kidney cancer working group.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24713

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24713

7 January 2021

based on heuristic

inferred from DOI database lookup

Estrogen, progesterone, and androgen-binding sites in renal cell carcinoma. Observations obtained in Phase II trial of flutamide

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24713

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase-II trial of 4-demethoxydaunorubicin (DMDR) for advanced hypernephroma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24713

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24713

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of trimetrexate in patients with advanced renal cell carcinoma. Clinical Community Oncology Program

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24713

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24713

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of Didemnin B in patients with advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24713

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase II trial of interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24713

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I/II trial of dexverapamil plus vinblastine for patients with advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24713

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of topotecan in patients with advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24713

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of liposomal encapsulated doxorubicin in patients with advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24713

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon alfa-2a and 13-cis-retinoic acid in renal cell carcinoma: antitumor activity in a phase II trial and interactions in vitro

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24713

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase II study of 13-cis-retinoic acid in patients with advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24713

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized multicenter phase II trial of subcutaneous recombinant human interleukin-12 versus interferon-alpha 2a for patients with advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24713

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24713

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of branched peginterferon-alpha 2a (40 kDa) for patients with advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24713

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of irofulven (6-hydroxymethylacylfulvene) for patients with advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24713

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of thalidomide for patients with advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24713

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of arsenic trioxide in patients with metastatic renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24713

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of bortezomib for patients with advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24713

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of pegylated interferon-alpha 2b in patients with advanced renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24713

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I/II Trial of Temsirolimus Combined With Interferon Alfa for Advanced Renal Cell Carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24713

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of lenalidomide in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24713

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase II trial of 17-(Allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24713

7 January 2021

based on heuristic

inferred from DOI database lookup

The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24713

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24713

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.24713

1 reference

Europe PubMed Central

13 May 2018

http://europepmc.org/abstract/MED/19921736

1 reference

Europe PubMed Central

13 May 2018

http://europepmc.org/abstract/MED/19921736

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53359385&oldid=1531339891"